S1PR1 and myeloid sarcoma: Its initial structure was optimized by means of chemical synthesis to increase its potency toward S1PR1 and selectivity for S1PR3, thereby increasing its therapeutic potential for MS and reducing the risk of side effects (Pan et al., 2013).